Chronic kidney disease and nonalcoholic fatty liver disease - Is there a link?

Gastroenterology Research and Practice

Volumn 2014, Issue , 2014, Pages

  Orlic L ^a   Mikolasevic, I ^a   Bagic, Z ^a   Racki, S ^a   Stimac, D ^a   Milic, S ^a  

^a KBC RIJEKA   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; NONALCOHOLIC FATTY LIVER; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW;

EID: 84897911147     PISSN: 16876121     EISSN: 1687630X     Source Type: Journal    
DOI: 10.1155/2014/847539     Document Type: Review

References (40)

1. Coresh J., Astor B. C., Greene T., Eknoyan G., Levey A. S., Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. American Journal of Kidney Diseases 2003 41 1 1 12 2-s2.0-0037228105 (Pubitemid 36043346)
2. Locatelli F., Pozzoni P., Tentori F., Del Vecchio L., Epidemiology of cardiovascular risk in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2003 18 7 vii2 vii9 2-s2.0-0042885532 (Pubitemid 37098602)
3. Hamad A. A., Khalil A. A., Connolly V., Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration. Arab Journal of Gastroenterology 2012 13 161 165
4. De Jager D. J., Grootendorst D. C., Jager K. J., Van Dijk P. C., Tomas L. M. J., Ansell D., Collart F., Finne P., Heaf J. G., De Meester J., Wetzels J. F. M., Rosendaal F. R., Dekker F. W., Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009 302 16 1782 1789 2-s2.0-70350741160 10.1001/jama.2009.1488
5. Sniderman A. D., Solhpour A., Alam A., Williams K., Sloand J. A., Cardiovascular death in dialysis patients: lessons we can learn from AURORA. Clinical Journal of the American Society of Nephrology 2010 5 2 335 340 2-s2.0-77949328411 10.2215/CJN.06300909
6. Vanholder R., Massy Z., Argiles A., Spasovski G., Verbeke F., Lameire N., Beige J., Brunet P., Cohen G., De Deyn P. P., Descamps-Latscha B., Herget-Rosenthal S., Hörl W., Jankowski J., Jörres A., Rodriguez M., Stegmayr B., Stenvinkel P., Wanner C., Weissinger E., Wiecek A., Zidek W., Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrology Dialysis Transplantation 2005 20 1048 1056 2-s2.0-20844434983 10.1093/ndt/gfh813 (Pubitemid 40862092)
7. Mikolasevic I., Racki S., Zaputovic l, Lukenda V., Milic S., Orlic L., Nonalcoholic fatty liver disease (NAFLD); a new risk factor for adverse cardiovascular events in dialysis patients. Medical Hypotheses 2014 82 205 208
8. Chalasani N., Younossi Z., Lavine J. E., The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Disease, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012 55 2005 2023
9. Farrell G. C., Larter C. Z., Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006 43 2 S99 S112 2-s2.0-33644547706 10.1002/hep.20973
10. Dowman J. K., Tomlinson J. W., Newsome P. N., Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics 2011 33 5 525 540 2-s2.0-79251524594 10.1111/j.1365-2036.2010.04556.x
11. Starley B. Q., Calcagno C. J., Harrison S. A., Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010 51 5 1820 1832 2-s2.0-77951456114 10.1002/hep.23594
12. Milic S., Stimac D., Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Digestive Diseases 2012 30 2 158 162 10.1159/000336669
13. Targher G., Arcaro G., Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis 2007 191 2 235 240 2-s2.0-33947108446 10.1016/j.atherosclerosis.2006.08.021 (Pubitemid 46400718)
14. Kim C. H., Younossi Z. M., Nonalcoholic fatty liver disease: a manifestation of the metabolic syndrome. Cleveland Clinic Journal of Medicine 2008 75 10 721 728 2-s2.0-54849436663 10.3949/ccjm.75.10.721
15. Mikolasevic I., Racki S., Lukenda V., Pavletic-Persic M., Milic S., Orlic L., Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction. Medical Hypotheses 2014 82 36 39
16. Mikolasevic I., Racki S., Bubic I., Jelic I., Stimac D., Orlic L., Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography. Kidney and Blood Pressure Research 2013 37 305 310
17. Targher G., Chonchol M., Zoppini G., Abaterusso C., Bonora E., Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? Journal of Hepatology 2011 54 5 1020 1029 2-s2.0-79954662342 10.1016/j.jhep.2010.11.007
18. Armstrong M. J., Adams L. A., Canbay A., Syn W. K., Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 2013 10.1002/hep.26717
19. Johns B. R., Pao A. C., Kim S. H., Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals. Nephrology Dialysis Transplantation 2012 27 4 1410 1415 2-s2.0-84859348886 10.1093/ndt/gfr498
20. Ferraro P. M., Lupo A., Yabarek T., Graziani M. S., Bonfante L., Abaterusso C., Gambaro G., Metabolic syndrome, cardiovascular disease, and risk for chronic kidney disease in an Italian cohort: analysis of the INCIPE study. Metabolic Syndrome and Related Disorders 2011 9 5 381 388 2-s2.0-80053531649 10.1089/met.2011.0040
21. Thomas G., Sehgal A. R., Kashyap S. R., Srinivas T. R., Kirwan J. P., Navaneethan S. D., Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clinical Journal of the American Society of Nephrology 2011 6 10 2364 2373 2-s2.0-80053920805 10.2215/CJN.02180311
22. Beddhu S., Kimmel P. L., Ramkumar N., Cheung A. K., Associations of metabolic syndrome with inflammation in CKD: results from the third National Health and Nutrition Examination Survey (NHANES III). American Journal of Kidney Diseases 2005 46 4 577 586 2-s2.0-25644439326 10.1053/j.ajkd.2005.06.014 (Pubitemid 41383935)
23. Pham H., Robinson-Cohen C., Biggs M. L., Ix J. H., Mukamal K. J., Fried L. F., Kestenbaum B., Siscovick D. S., de Boer I. H., Chronic kidney disease, Insulin resistance, and incident diabetes in older adults. Clinical Journal of the American Society of Nephrology 2012 7 4 588 594 2-s2.0-84859518313 10.2215/CJN.11861111
24. Cheng H.-T., Huang J.-W., Chiang C.-K., Yen C.-J., Hung K.-Y., Wu K.-D., Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly. Journal of Clinical Endocrinology and Metabolism 2012 97 4 1268 1276 2-s2.0-84859543673 10.1210/jc.2011-2658
25. Targher G., Bertolini L., Rodella S., Zoppini G., Lippi G., Day C., Muggeo M., Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 2008 51 3 444 450 2-s2.0-39049102073 10.1007/s00125-007-0897-4
26. Targher G., Bertolini L., Chonchol M., Rodella S., Zoppini G., Lippi G., Zenari L., Bonora E., Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 2010 53 7 1341 1348 2-s2.0-77955665639 10.1007/s00125-010-1720-1
27. Hwang S. T., Cho Y. K., Yun J. W., Park J. H., Kim H. J., Park D. I., Sohn C. I., Jeon W. K., Kim B. I., Rhee E. J., Oh K. W., Lee W. Y., Jin W., Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Internal Medicine Journal 2010 40 6 437 442 2-s2.0-77953838107 10.1111/j.1445-5994.2009.01979.x
28. Targher G., Kendrick J., Smits G., Chonchol M., Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutrition, Metabolism and Cardiovascular Diseases 2010 20 8 583 590 2-s2.0-77955654684 10.1016/j.numecd.2009.05.012
29. Yun K. E., Shin C. Y., Yoon Y. S., Park H. S., Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis 2009 205 2 533 537 2-s2.0-67650912354 10.1016/j.atherosclerosis.2008.12.012
30. Lee D. S., Evans J. C., Robins S. J., Gamma-glutamyltransferase and metabolic syndrome, cardiovascular disease, and mortality risk. The Framingham Heart study. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 127 133 (Pubitemid 46360389)
31. Yilmaz Y., Alahdab Y. O., Yonal O., Kurt R., Kedrah A. E., Celikel C. A., Ozdogan O., Duman D., Imeryuz N., Avsar E., Kalayci C., Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism 2010 59 9 1327 1330 2-s2.0-77956625813 10.1016/j.metabol.2009.12.012
32. Manco M., Ciampalini P., DeVito R., Vania A., Cappa M., Nobili V., Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease. Pediatric Nephrology 2009 24 6 1211 1217 2-s2.0-67650320852 10.1007/s00467-009-1134-9
33. Targher G., Bertolini L., Rodella S., Lippi G., Zoppini G., Chonchol M., Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clinical Journal of the American Society of Nephrology 2010 5 12 2166 2171 2-s2.0-78650323871 10.2215/CJN.05050610
34. Targher G., Chonchol M., Bertolini L., Rodella S., Zenari L., Lippi G., Franchini M., Zoppini G., Muggeo M., Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. Journal of the American Society of Nephrology 2008 19 8 1564 1570 2-s2.0-49649090452 10.1681/ASN.2007101155
35. Ryu S., Chang Y., Kim D.-I., Kim W. S., Suh B.-S., γ -glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clinical Chemistry 2007 53 1 71 77 2-s2.0-33846007117 10.1373/clinchem.2006.078980 (Pubitemid 46055179)
36. Sasso M., Beaugrand M., de Ledinghen V., Douvin C., Marcellin P., Poupon R., Sandrin L., Miette V., Controlled attenuation parameter (CAP): a novel VCTE ™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound in Medicine and Biology 2010 36 11 1825 1835 2-s2.0-77958154016 10.1016/j.ultrasmedbio.2010.07.005
37. Kronenberg F., Emerging risk factors and markers of chronic kidney disease progression. Nature Reviews Nephrology 2009 5 12 677 689 2-s2.0-73849124981 10.1038/nrneph.2009.173
38. Ix J. H., Sharma K., Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. Journal of the American Society of Nephrology 2010 21 3 406 412 2-s2.0-77949882555 10.1681/ASN.2009080820
39. Lonardo A., Carani C., Carulli N., Loria P., 'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis. Journal of Hepatology 2006 44 6 1196 1207 2-s2.0-33646128472 10.1016/j.jhep.2006.03.005
40. Georgescu E. F., Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? Advances in Therapy 2008 25 11 1141 1174 2-s2.0-66549124116 10.1007/s12325-008-0110-2